WO2001021162A3 - Treating allergic and inflammatory conditions using desloratadine - Google Patents

Treating allergic and inflammatory conditions using desloratadine Download PDF

Info

Publication number
WO2001021162A3
WO2001021162A3 PCT/US2000/025609 US0025609W WO0121162A3 WO 2001021162 A3 WO2001021162 A3 WO 2001021162A3 US 0025609 W US0025609 W US 0025609W WO 0121162 A3 WO0121162 A3 WO 0121162A3
Authority
WO
WIPO (PCT)
Prior art keywords
desloratadine
allergic
inflammatory conditions
treating allergic
baseline
Prior art date
Application number
PCT/US2000/025609
Other languages
French (fr)
Other versions
WO2001021162A2 (en
Inventor
Kim Allen Heithoff
Original Assignee
Schering Corp
Kim Allen Heithoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Kim Allen Heithoff filed Critical Schering Corp
Priority to AU75897/00A priority Critical patent/AU7589700A/en
Priority to CA002383214A priority patent/CA2383214A1/en
Priority to JP2001524588A priority patent/JP2003509459A/en
Priority to EP00965127A priority patent/EP1214071A2/en
Publication of WO2001021162A2 publication Critical patent/WO2001021162A2/en
Publication of WO2001021162A3 publication Critical patent/WO2001021162A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of desloratadine for the preparation of a medicament for substantially returning work-related performance and/or workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin airway passages, e.g., season allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma to the person's baseline work-related performance and baseline workplace productivity.
PCT/US2000/025609 1999-09-22 2000-09-19 Treating allergic and inflammatory conditions using desloratadine WO2001021162A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU75897/00A AU7589700A (en) 1999-09-22 2000-09-19 Treating allergic and inflammatory conditions
CA002383214A CA2383214A1 (en) 1999-09-22 2000-09-19 Treating allergic and inflammatory conditions
JP2001524588A JP2003509459A (en) 1999-09-22 2000-09-19 Treatment of allergic and inflammatory conditions
EP00965127A EP1214071A2 (en) 1999-09-22 2000-09-19 Treating allergic and inflammatory conditions using desloratadine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40059999A 1999-09-22 1999-09-22
US09/400,599 1999-09-22

Publications (2)

Publication Number Publication Date
WO2001021162A2 WO2001021162A2 (en) 2001-03-29
WO2001021162A3 true WO2001021162A3 (en) 2002-03-07

Family

ID=23584252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025609 WO2001021162A2 (en) 1999-09-22 2000-09-19 Treating allergic and inflammatory conditions using desloratadine

Country Status (7)

Country Link
EP (1) EP1214071A2 (en)
JP (1) JP2003509459A (en)
AR (1) AR025724A1 (en)
AU (1) AU7589700A (en)
CA (1) CA2383214A1 (en)
PE (1) PE20010752A1 (en)
WO (1) WO2001021162A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659716A (en) * 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
WO1998006394A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
WO1998034614A1 (en) * 1997-02-07 1998-08-13 Sepracor, Inc. Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
WO1998048803A1 (en) * 1997-04-25 1998-11-05 Schering-Plough Kabushiki Kaisha Eyedrops
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659716A (en) * 1984-02-15 1987-04-21 Schering Corporation Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
WO1998006394A1 (en) * 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
WO1998034614A1 (en) * 1997-02-07 1998-08-13 Sepracor, Inc. Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
WO1998048803A1 (en) * 1997-04-25 1998-11-05 Schering-Plough Kabushiki Kaisha Eyedrops
EP0978281A1 (en) * 1997-04-25 2000-02-09 Schering-Plough Kabushiki Kaisha Eyedrops

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENOVESE: "loratadine and desethoxycarbonyl loratadine...", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 27, no. 5, 1997, pages 559 - 567, XP000998792 *
HANDLEY DEAN A ET AL: "Methods for treating dermatitis using descarboethoxyloratadine.", 25 April 2000, OFFICIAL GAZETTE OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, VOL. 1233, NR. 4, PAGE(S) NO PAGINATION, APR. 25, 2000, ISSN: 0098-1133, XP000997862 *
MOLET, S. ET AL: "Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells", CLIN. EXP. ALLERGY ( 1997 ), 27(10), 1167-1174, XP000997866 *

Also Published As

Publication number Publication date
CA2383214A1 (en) 2001-03-29
WO2001021162A2 (en) 2001-03-29
PE20010752A1 (en) 2001-07-17
JP2003509459A (en) 2003-03-11
EP1214071A2 (en) 2002-06-19
AR025724A1 (en) 2002-12-11
AU7589700A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
AU2003243224A1 (en) Methods of improving the softness of fibers and nonwoven webs and fibers and nonwoven webs havinb improved softness
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
WO2002066427A3 (en) (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
AU2003237933A1 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
WO2001082788A3 (en) Compounds and methods for the treatment and prevention of bacterial infection
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
HK1053058A1 (en) Use of pramipexole for the treatment of addictive disorders
AU2003269413A1 (en) Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
EP1440689A3 (en) Treatment of neurotic disorders
MXPA05001885A (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis.
EP1406648A4 (en) The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
WO2000009098A3 (en) Method for treating ocular neovascular diseases
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
WO2001021162A3 (en) Treating allergic and inflammatory conditions using desloratadine
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
WO2000066096A3 (en) Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
WO2004010924A3 (en) Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
AU5403099A (en) Method for controlling the use of furniture to sit or lie on, put at users' disposal and piece of furniture used therewith
WO2000061125A3 (en) Osanetant in the treatment of mood disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2383214

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 524588

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10088629

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003023

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000965127

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965127

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000965127

Country of ref document: EP